Ingenious “molecular movie” reveals how penicillin works

An international team of scientists has created a molecular movie of an enzyme building a key structure found in penicillin antibiotics, capturing fleeting chemical reactions that have never been seen before in such detail.


Using powerful X-rays, researchers from the University of Oxford in collaboration with partners from the XFEL Hub at Diamond Light Source, Lawrence Berkeley National Laboratory, PAL-XFEL and SLAC National Accelerator Laboratory, captured the enzyme in action, revealing the unexpected process of how nature builds its antibiotic structure. 

By taking a series of ultrafast X-ray snapshots, the researchers were able to piece together a molecular movie showing the previously unseen rapid chemical stages in the formation of β-lactam antibiotics like penicillin. 

The study, published in Nature Catalysis, focuses on isopenicillin N synthase (IPNS), an enzyme responsible for a crucial step in the biosynthesis of penicillin antibiotics.  

The work is the result of more than a decade of international collaboration and reveals unexpected aspects of the chemistry that could help inform the development of new antibiotics and other therapeutics. 

Read more on the Diamond and SLAC websites

Image: Structure of the human enzyme AspH. The enlarged view shows the enzyme’s iron-containing active site (orange sphere) bound to its protein substrate. Using time resolved X-ray crystallography, the researchers observed how AspH activates oxygen and hydroxylates proteins, providing new insight into a family of enzymes involved in oxygen sensing, development and cancer.

Credit: Patrick Rabe/University of Oxford and Greg Stewart/SLAC National Accelerator Laboratory

Toxic behaviour: why do tuberculosis bacteria poison themselves?

Tuberculosis bacteria halt their growth with self-toxins that could inspire novel therapeutics

Stealthy bacteria slow down their division when they invade the body to avoid drawing the immune system’s attention. Mycobacterium tuberculosis, the world’s leading bacterial infectious killer, takes a seemingly counterintuitive approach to that end. M. tuberculosis expresses self-toxins that damage its DNA and shut down growth as well as antitoxins to later help recuperate and resume proliferation. By studying these toxin-antitoxin pairs, Durham University microbiologist Professor Tim Blower aims to find ways to mimic the self-toxins with new therapeutics

By conducting X-ray crystallography at Diamond’s I04 beamline, Blower and his colleagues uncovered the structure of toxin-antitoxin complexes, providing insight into how they regulate DNA damaging activity. The findings reveal that the protein pair potentially form two types of complexes. A grouping of two toxins and four antitoxins dominated at body temperature, whereas an equal pairing of two and two were more common in colder conditions, which may reflect how the proteins come together when bacteria live in the environment. These findings change our perspective on how the toxins and antitoxins operate, bringing researchers closer to designing new drugs against a pandemic microbe that continuously evolves resistance to existing antibiotics. 

Each year, Mycobacterium tuberculosis leads approximately 10 million people to endure a bloody cough, exhaustion, and fever, and it causes over one million deaths. Doctors typically prescribe patients a course of four to six antibiotics to clear the infection, but the bacteria evolve mechanisms to resist the effects of the drugs. As many as 2.5 percent of tuberculosis patients carry variants of the bacteria resistant to the four most common first-line antibiotics, and that proportion is expected to climb if researchers don’t develop other therapeutics that could kill resistant strains.    

Poison control

Blower and the team from Durham University and Newcastle University study mechanisms the bacteria use to limit their own growth in pursuit of inspiration for new drug candidates. Specifically, they focus on an enzyme that controls DNA organisation in the cell and a pair of toxins and antitoxins that regulate this enzyme’s function. 

Bacteria and eukaryotes (for instance, humans), organise DNA in the cell differently. Eukaryotic DNA is tightly packaged in the nucleus by histone proteins that wind it up into compact chromosomes. Bacteria, on the other hand, lack histones and rely on DNA to undergo a process called supercoiling. Like how a wound-up rubber band contracts into a small volume, bacterial DNA winds up into a condensed coil to save space. However, supercoiled DNA needs constant maintenance, which involves occasional unwinding and rewinding of the molecules. To this end, an essential enzyme called DNA gyrase cuts the DNA, allows it to untwist, and glues the cut ends back together again, so they can coil again. 

Repairing the DNA breaks is essential to the bacteria’s survival because it avoids the build-up of harmful DNA damage and mutations, but sometimes M. tuberculosis interferes with the process. It achieves this using a toxin-antitoxin system that inhibits DNA gyrase. Scientists are still uncertain about the biological role of the toxin, Blower said, but one hypothesis is that by partially shutting down bacterial growth, it prevents antibiotics that target growth machinery from working. Another is that the toxin helps quiescent bacteria evade immune detection as slow-growing microbes tend to slip under the radar. The antitoxin relieves the bacteria, allowing those that survived the accumulation of DNA breaks to seal them back together and resume growth when conditions in the body become favourable. 

Researchers developing new therapeutics are drawn to these systems. Suggesting scientists could develop copycat drugs, Professor Blower said: 

If these toxins are so effective at killing, then we should take advice from nature and work out how they work.

Read more on Diamond website

Unlocking the doors to effective COVID-19 treatments

Developing therapeutics for COVID-19 should lessen the length and severity of the illness, keeping more people out of the hospital and improving patient outcomes.

A team of interdisciplinary researchers from the Institut National de la Recherche Scientifique (INRS) are hoping to identify effective COVID-19 therapeutics. With help from the Canadian Light Source (CLS) at the University of Saskatchewan, the team has been able to visualize the interaction between inhibitory molecules and viral proteins. This allows researchers to see if their drug designs work as intended.

“We have libraries of molecular fragments and drug candidates that we are testing,” said Michael Maddalena, a research intern in Steven LaPlante’s lab at INRS. “We are screening to see if they are active and actually stick to the virus’ proteins or to essential human receptors where we think there are opportunities for drugs.”

This research targets the proteins of the SARS-CoV-2 virus that are involved in its replication and survival. Their work also targets the essential human receptors that the virus depends on to enter human cells. Drugs that stick to human receptors are unlikely to be susceptible to viral mutants — ensuring that new therapeutics will be effective against new variants.

Read more on the CLS website

Image: The LaPlante research team